IDH2 and oligodendroglioma: For further details, refer to the FDA announcement: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation (accessed on 12 November 2024).